|
Report Date : |
20.09.2014 |
IDENTIFICATION DETAILS
|
Name : |
APEX PHARMACEUTICALS PVT. LTD |
|
|
|
|
Registered Office : |
13/45, Adarsh Nagar Birganj |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
15.07.2013 |
|
|
|
|
Date of Incorporation : |
19.06.1994 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacturer of pharmaceutical products. |
|
|
|
|
No. of Employees : |
200 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 1, 2014
|
Country Name |
Previous Rating (31.03.2014) |
Current Rating (01.06.2014) |
|
Nepal |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
NEPAL - ECONOMIC OVERVIEW
Nepal is among the poorest
and least developed countries in the world, with about one-quarter of its
population living below the poverty line. Nepal is heavily dependent on remittances,
which amount to as much as 22-25% of GDP. Agriculture is the mainstay of the
economy, providing a livelihood for more than 70% of the population and
accounting for a little over one-third of GDP. Industrial activity mainly
involves the processing of agricultural products, including pulses, jute,
sugarcane, tobacco, and grain. Nepal has considerable scope for exploiting its
potential in hydropower, with an estimated 42,000 MW of commercially feasible
capacity, but political uncertainty and a difficult business climate have
hampered foreign investment. Additional challenges to Nepal's growth include
its landlocked geographic location, persistent power shortages, underdeveloped
transportation infrastructure, civil strife and labor unrest, and its susceptibility
to natural disaster. The lack of political consensus in the past several years
has delayed national budgets and prevented much-needed economic reform,
although the government passed a full budget in 2013
|
Source
: CIA |
APEX PHARMACEUTICALS
PVT. LTD
13/45, ADARSH NAGAR
BIRGANJ (NEPAL)
TEL : +977-51-529355/ 534173
FAX: +977-51-529377
Office Email : info@apexpharma.com.np
FACTORY ADDRESS
Parwanipur Nepal
History : It is a private limited company incorporated at Kathmandu under His Majesty Govt.
Act No.2767 of 19.06.1994.
Pan No : 300077609
Directors : 1. Vinay Kabra
Rajendra Kabra
Bankers : 1. Nepal Bank Ltd., Kathmandu (Nepal)
Nepal Grindlays Bank, Kathmandu (Nepal)
Nepal Banijya Bank, Kathmandu (Nepal)
Shareholders : Director and Their relative hold all shares.
Auditors: J P and Khandelwal and Company, Kathmandu (Nepal)
Importer of Raw Material
Country India and China
Apex pharmaceutical was established in the year 2052 as a pharmaceuticals manufacturing company with a vision to serve the nation & its population with high quality medicines at an affordable price. The production unit has been backed up with family automatic liquid line, blister, strip, machine for capsule& tablet dosage for dry syrup and ointment manufacturing unit to meet the optimum demand of the population. Apex pharmaceuticals as one of the leading pharmaceuticals manufacturing company has established its credibility among the medicals fraternity & has earned the confidence of leading practitioners medical consultants, doctor & celebrities of medical field with its range of quality medicine and has been recognized as one of fastest growing company in the Pharma industry.
Apex pharmaceuticals has
a privilege of introducing many pioneer national brands in the category of
antispasmodic, amoebicides, antipyretic, Antibiotics, derma preparations &
antiulcerants with its indigenous technology & highly qualified &
competent team of pharmacist with a vision of providing medication at a most
affordable cost for better public healthcare.
Apex emerged with a plan of attaining WHO/GMP by the end of 2062 & has been
finally involved in equipping itself with all pre requisites for WHO/GMP.
Apex is on of the professionally managed with team of professionals and manufacturing various penicillin, non penicillin dosage forms such as tablets, Capsules, dry syrup, liquids & optimum range of products & has a plan of expanding its unit with more efficient & high-tech machines for fundamental growth in quality as well as in production to cater the product to different parts of the country as well as to export in future.
Apex with the help of its qualified & experienced team of pharmacist
has been strictly abiding in accordance to the GMP norms for production of
medicines with a motto "Quality in totality”. .
Apex has a very well equipped and self sufficient in house laboratory for
ensuring high quality control in production, where modern and sophiscated
apparatus are being operated by technically qualified & highly competent
professionals to ensure the corporate motive of "Quality in
totality. . .
For ethical and genuine promotion of its range of products the company has two marketing wings one is Pharma Division & other Pulsar with a strongly diversified strategy for ethical promotion of its safe, efficacious and quality medicines at different level of medicals fraternity for much better public health.
The products are living catered to different parts of the country through authorized whole sale dealer/ stockiest with a help of professional marketing team.
Apex has always channalised its businesses through qualified professional of related field & could create a mile stone in achieving overall excellence with the help of in excellent team work. Which leads towards, the achievement of its corporate goal. Apex strongly believes on up gradation of its employee and continuous progress in every sector of operation & to equip with better technology to increase in knowledge and efficiency of an individual. The company has been contenting seminars & trainings periodically.
Apex is proud to have some the products which have paved the path for freedoms growth of molecule as a whole.
Trade trams : Germany, UK, Swizerland.
BALANCE SHEET AS AT 15th JULY, 2013
Authorised Capital :
50,000,000/- (5,000,000
Equity Shares of
Rs.10/- each)
Paidup : 42,287,500/- (4228750 of Rs.10/- each
|
BALANCE SHEET AS AT 31.07.2013 |
||||
|
|
|
|
|
|
|
Liabilities |
Amount (Rs.) |
|
Assets |
Amount (Rs.) |
|
|
|
|
|
|
|
Paid up Capital |
42,287,500 |
|
Fixed Assets |
173,270,691 |
|
Reserve & Surplus |
162,800,580 |
|
CIP |
31,385,910 |
|
Secured Loan |
229,966,660 |
|
Investments |
48,100 |
|
Unsecured Loan |
13,090,456 |
|
Inventories |
110,466,523 |
|
Current Liabilities |
179,792,336 |
|
Sundry Debtors |
157,911,079 |
|
Provisions |
451,888 |
|
Cash at Bank |
13,402,463 |
|
|
|
|
Loans & Advances |
141,904,654 |
|
Total |
628,389,420 |
|
|
628,389,420 |
|
|
|
|
|
|
|
|
Rs. |
|
|
|
|
Sales |
1,156,703,268 |
|
|
|
|
Profit before Tax |
61,884,897 |
|
|
|
|
Profit after Tax |
61,443,054 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments are reported to be correct and regular as per commitments. Trade relations are fair. Consider good for normal business engagement.
|
NAME |
Mr. N M Sharma |
|
DESIGNATION |
Accounts Manager |
|
CONTACT NO |
000977-51-529355 |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.60.80 |
|
|
1 |
Rs.100.06 |
|
Euro |
1 |
Rs.78.46 |
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
NIS |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.